Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer in PALOMA-3Eur. J. Cancer 2018 Nov 01;104(xx)21-31, M Cristofanilli, A DeMichele, C Giorgetti, NC Turner, DJ Slamon, SA Im, N Masuda, S Verma, S Loi, M Colleoni, KP Theall, X Huang, Y Liu, CH Bartlett
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.